Laura Eds Edstrom-Smith
Family · West Palm Beach, FLNPI 1336659671
Payments from drug & device makers
Across 138 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$467
- Bayer$254
- Sanofi-aventis U.S. LLC$157
- Boehringer Ingelheim$141
- AbbVie$139
- Lilly USA, LLC$129
- plus $845 from 21 others
What the payments were for
- Food & beverage$2,133100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $467 |
| Bayer | 15 | $254 |
| Sanofi-aventis U.S. LLC | 8 | $157 |
| Boehringer Ingelheim | 8 | $141 |
| AbbVie | 8 | $139 |
| Lilly USA, LLC | 11 | $129 |
| AstraZeneca | 9 | $115 |
| GSK | 7 | $96 |
| Eisai Inc. | 6 | $90 |
| Novartis | 5 | $70 |
| Pfizer | 4 | $60 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Merck | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Amgen | 2 | $28 |
| Corcept Therapeutics | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Biogen | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| PBG Puerto Rico LLC | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
How this compares
$2,133 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $35,504 |
| EliquisApixaban | 13 | $17,744 |
| LinzessLinaclotide | 14 | $12,669 |
| OzempicSemaglutide | 15 | $12,581 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,157 |
| Pravastatin Sodium | 78 | $948 |
| Omeprazole | 58 | $876 |
| Gabapentin | 34 | $781 |
| Tamsulosin Hcl | 49 | $727 |
| Methylprednisolone | 106 | $713 |
| Atorvastatin Calcium | 92 | $705 |
| Levothyroxine Sodium | 55 | $587 |
| Losartan Potassium | 52 | $554 |
| Amlodipine Besylate | 105 | $499 |
| Azelastine Hcl | 18 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $96 | $35,50429 claims |
| PfizerEliquis | $60 | $17,74413 claims |
| AbbVieLinzess | $139 | $12,66914 claims |
| Novo NordiskOzempic | $467 | $12,58115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in West Palm Beach
- Katharine TamburroWest Palm Beach$67K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.